BOLETÍN BIBLIOGRÁFICO BIBLIOTECA DE SALUD DR. BOGOSLAV JURICIC TURINA

Boletín Bibliográfico Nº6/ Agosto 2014

La Biblioteca de Salud “Dr. Bogoslav Juricic Turina, dependiente de la División de Planificación Sanitaria del Ministerio de Salud, tiene el agrado de enviar a usted, el Boletín Bibliográfico Nº6/2014. (En el título seguir el vínculo del texto completo). Invitamos a consultar la Biblioteca Virtual en: www.bibliotecaminsal.cl.

VIRUS EBOLA

1. Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.

Garamszegi S, Yen JY, Honko AN, Geisbert JB, Rubins KH, Geisbert TW, Xia Y, Hensley LE, Connor JH. PLoS Negl Trop Dis. 2014 Jul 31; 8(7):e3061.

2. Outbreak of ebola virus disease in Guinea: where ecology meets economy.

Bausch DG, Schwarz L.

PLoS Negl Trop Dis. 2014 Jul 31;8 (7):e3056.

3. Spatial localization of the Ebola glycoprotein mucin-like domain using cryo-electron tomography.

Tran EE, Simmons JA, Bartesaghi A, Shoemaker CJ, Nelson E, White JM, Subramaniam S.

J Virol. 2014 Jul 9.

4. Ebola Outbreak Response; Experience and Development of Screening Tools for Viral Haemorrhagic Fever (VHF) in a HIV Center of Excellence Near to VHF Epicentres.

Parkes-Ratanshi R, Elbireer A, Mbambu B, Mayanja F, Coutinho A, Merry C.

PLoS One. 2014 Jul 9; 9 (7):e100333.

5. Membrane binding and bending in Ebola VP40 assembly and egress.

Stahelin RV.

Front Microbiol. 2014 Jun 18; 5:300.

6. Clock Rooting Further Demonstrates that Guinea 2014 EBOV is a Member of the Zaïre Lineage.

Calvignac-Spencer S, Schulze JM, Zickmann F, Renard BY.

PLoS Curr. 2014 Jun 16; 6.

7. Ebola viral disease outbreak - west Africa, 2014.

Dixon MG, Schafer IJ; EIS officer, CDC.

MMWR Morb Mortal Wkly Rep. 2014 Jun 27;63 (25):548-51.

8. Undiagnosed acute viral febrile illnesses, sierra leone.

Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN.

Emerg Infect Dis. 2014 Jul; 20(7):1176-82.

9. Role of Protein Phosphatase 1 in Dephosphorylation of Ebola Virus VP30 and its Targeting for the Inhibition of Viral Transcription.

Ilinykh PA, Tigabu B, Ivanov A, Ammosova T, Obukhov Y, Garron T, Kumari N, Kovalskyy D, Platonov MO, Naumchik VS, Freiberg AN, Nekhai S, Bukreyev A.

J Biol Chem. 2014 Jun 16.

10. Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus.

Becquart P, Mahlakõiv T, Nkoghe D, Leroy EM.

PLoS One. 2014 Jun 10; 9(6):e96360.

11. Outbreak news. Ebola virus disease, West Africa.

[No authors listed]

Wkly Epidemiol Rec. 2014 May 16; 89(20):205-6. English, French.

12. Phylogenetic Analysis of Guinea 2014 EBOV Ebolavirus Outbreak.

Dudas G, Rambaut A.

PLoS Curr. 2014 May 2; 6.

13. Ebola - A Growing Threat?

Feldmann H.

N Engl J Med. 2014 May 7.

14. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Mire CE, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM, Fritz EA, Feldmann H, Hensley LE, Geisbert TW.

PLoS One. 2014 Apr 23; (4):e94355.

15. Bat flight and zoonotic viruses.

O'Shea TJ, Cryan PM, Cunningham AA, Fooks AR, Hayman DT, Luis AD, Peel AJ, Plowright RK, Wood JL.

Emerg Infect Dis. 2014 May; 20(5):741-5.

16. Filoviruses in bats: current knowledge and future directions.

Olival KJ, Hayman DT.

Viruses. 2014 Apr 17; 6(4):1759-88.

17. Emergence of Zaire Ebola Virus Disease in Guinea - Preliminary Report.

Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S.

N Engl J Med. 2014 Apr 16.

18. Analysis of determinants in filovirus glycoproteins required for tetherin antagonism.

Gnirß K, Fiedler M, Krämer-Kühl A, Bolduan S, Mittler E, Becker S, Schindler M, Pöhlmann S.

Viruses. 2014 Apr 9; (4):1654-71.

19. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses.

Uebelhoer LS, Albariño CG, McMullan LK, Chakrabarti AK, Vincent JP, Nichol ST, Towner JS.

Antiviral Res. 2014 Jun; 106:86-94.

20. Diverse viral glycoproteins as well as CD4 co-package into the same human immunodeficiency virus (HIV-1) particles.

Gregory DA, Olinger GY, Lucas TM, Johnson MC.

Retrovirology. 2014 Apr 3; 11:28.

21. Structure of the Reston ebolavirus VP30 C-terminal domain.

Clifton MC, Kirchdoerfer RN, Atkins K, Abendroth J, Raymond A, Grice R, Barnes S, Moen S, Lorimer D, Edwards TE, Myler PJ, Saphire EO.

Acta Crystallogr F Struct Biol Commun. 2014 Apr; 70(Pt 4):457-60.

22. The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway.

Edwards MR, Johnson B, Mire CE, Xu W, Shabman RS, Speller LN, Leung DW, Geisbert TW, Amarasinghe GK, Basler CF.

Cell Rep. 2014 Mar 27; 6(6):1017-25.

23. Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.

Martins KA, Steffens JT, van Tongeren SA, Wells JB, Bergeron AA, Dickson SP, Dye JM, Salazar AM, Bavari S.

PLoS One. 2014 Feb 24; 9(2):e89735.

24. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.

Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S.

Antiviral Res. 2014 May; 105:17-21.

25. Clinical documentation and data transfer from Ebola and Marburg virus disease wards in outbreak settings: health care workers' experiences and preferences.

Bühler S, Roddy P, Nolte E, Borchert M.

Viruses. 2014 Feb 19; 6(2):927-37.

26. Emerging filoviral disease in Uganda: proposed explanations and research directions.

Polonsky JA, Wamala JF, de Clerck H, Van Herp M, Sprecher A, Porten K, Shoemaker T.

Am J Trop Med Hyg. 2014 May; 90(5):790-3.

27. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.

Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W.

MBio. 2014 Jan 28; 5(1):e00862-13.

28. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.

Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW.

PLoS Negl Trop Dis. 2013 Dec 19; 7(12):e2600.

29. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb.

Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S, Alimonti JB, Kobinger GP.

Sci Rep. 2013 Nov 28; 3:3365.

30. Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry.

Wen Z, Zhao B, Song K, Hu X, Chen W, Kong D, Ge J, Bu Z.

Virol J. 2013 Nov 9; 10:331.

31. Correction: Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection.

Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM.

PLoS One. 2013 Oct 1;8(10).

32. Ebola virus RNA editing depends on the primary editing site sequence and an upstream secondary structure.

Mehedi M, Hoenen T, Robertson S, Ricklefs S, Dolan MA, Taylor T, Falzarano D, Ebihara H, Porcella SF, Feldmann H.

PLoS Pathog. 2013; 9(10):e1003677.

33. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models.

Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, Montefiori DC, Vojdani F, McCormick AA, O'Keefe BR, Palmer KE.

Antimicrob Agents Chemother. 2014; 58(1):120-7.

34. Characterization of the envelope glycoprotein of a novel filovirus, lloviu virus.

Maruyama J, Miyamoto H, Kajihara M, Ogawa H, Maeda K, Sakoda Y, Yoshida R, Takada A.

J Virol. 2014 Jan; 88(1):99-109.

35. The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication.

Hill-Batorski L, Halfmann P, Neumann G, Kawaoka Y.

J Virol. 2013 Dec; 87(24):13795-802.

36. Hospital-based surveillance for viral hemorrhagic fevers and hepatitides in Ghana.

Bonney JH, Osei-Kwasi M, Adiku TK, Barnor JS, Amesiya R, Kubio C, Ahadzie L, Olschläger S, Lelke M, Becker-Ziaja B, Pahlmann M, Günther S.

PLoS Negl Trop Dis. 2013 Sep. 19; 7(9):e2435.

37. A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses.

Koehler JW, Smith JM, Ripoll DR, Spik KW, Taylor SL, Badger CV, Grant RJ, Ogg MM, Wallqvist A, Guttieri MC, Garry RF, Schmaljohn CS.

PLoS Negl Trop Dis. 2013 Sep. 12; 7(9):e2430.

38. Suppression of PACT-induced type I interferon production by herpes simplex virus 1 Us11 protein.

Kew C, Lui PY, Chan CP, Liu X, Au SW, Mohr I, Jin DY, Kok KH.

J Virol. 2013 Dec; 87(24):13141-9.

39. Animal models for Ebola and Marburg virus infections.

Nakayama E, Saijo M.

Front Microbiol. 2013 Sep 5 ;4:267.

40. Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances.

Schudt G, Kolesnikova L, Dolnik O, Sodeik B, Becker S.

Proc Natl Acad Sci U S A. 2013 Aug 27; (35):14402-7.

41. Persistent immune responses after Ebola virus infection.

Sobarzo A, Ochayon DE, Lutwama JJ, Balinandi S, Guttman O, Marks RS, Kuehne AI, Dye JM, Yavelsky V, Lewis EC, Lobel L.

N Engl J Med. 2013 Aug 1; (5):492-3.

42. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome.

Luthra P, Ramanan P, Mire CE, Weisend C, Tsuda Y, Yen B, Liu G, Leung DW, Geisbert TW, Ebihara H, Amarasinghe GK, Basler CF.

Cell Host Microbe. 2013 Jul 17; (1):74-84.

43. Duration of Maternal Antibodies against Canine Distemper Virus and Hendra Virus in Pteropid Bats.

Epstein JH, Baker ML, Zambrana-Torrelio C, Middleton D, Barr JA, Dubovi E, Boyd V, Pope B, Todd S, Crameri G, Walsh A, Pelican K, Fielder MD, Davies AJ, Wang LF, Daszak P.

PLoS One. 2013 Jun 27;8(6):e67584.

44. Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism.

Bale S, Julien JP, Bornholdt ZA, Krois AS, Wilson IA, Saphire EO.

J Virol. 2013 Sep;87 (18):10385-8.

45. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG.

Sci Transl Med. 2013 Jun 19; 5 (190):190ra79.

46. Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection.

Chen H, Zheng D, Abbott J, Liu L, Bartee MY, Long M, Davids J, Williams J, Feldmann H, Strong J, Grau KR, Tibbetts S, Macaulay C, McFadden G, Thoburn R, Lomas DA, Spinale FG, Virgin HW, Lucas A.

Antimicrob Agents Chemother. 2013 Sep; 57 (9):4114-27. Epub 2013 Jun 17.

47. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ.

PLoS Pathog. 2013; 9(5):e1003389.

48. Late endosomal transport and tethering are coupled processes controlled by RILP and the cholesterol sensor ORP1L.

van der Kant R, Fish A, Janssen L, Janssen H, Krom S, Ho N, Brummelkamp T, Carette J, Rocha N, Neefjes J.

J Cell Sci. 2013 Aug 1; 126(Pt 15):3462-74.

49. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry.

Moller-Tank S, Kondratowicz AS, Davey RA, Rennert PD, Maury W.

J Virol. 2013 Aug; (15):8327-41.

50. The secret life of viral entry glycoproteins: moonlighting in immune evasion.

Cook JD, Lee JE.

PLoS Pathog. 2013; 9(5):e1003258.

51. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.

Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, Villarreal DO, Myles DJ, Croyle MA, Yan J, Kobinger GP, Weiner DB.

Mol Ther. 2013 Jul; 21(7):1432-44.

52. The Ebola virus matrix protein deeply penetrates the plasma membrane: an important step in viral egress.

Soni SP, Adu-Gyamfi E, Yong SS, Jee CS, Stahelin RV.

Biophys J. 2013 May 7; 104(9):1940-9.

53. DNA topoisomerase 1 facilitates the transcription and replication of the Ebola virus

genome.

Takahashi K, Halfmann P, Oyama M, Kozuka-Hata H, Noda T, Kawaoka Y.

J Virol. 2013 Aug; 87(16):8862-9.

54. Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids.

Regula LK, Harris R, Wang F, Higgins CD, Koellhoffer JF, Zhao Y, Chandran K, Gao J, Girvin ME, Lai JR.

Biochemistry. 2013 May 21; (20):3393-404.

55. Host IQGAP1 and Ebola virus VP40 interactions facilitate virus-like particle egress.

Lu J, Qu Y, Liu Y, Jambusaria R, Han Z, Ruthel G, Freedman BD, Harty RN.

J Virol. 2013 Jul; 87(13):7777-80.

56. Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs.

Nfon CK, Leung A, Smith G, Embury-Hyatt C, Kobinger G, Weingartl HM.

PLoS One. 2013 Apr 23; (4):e61904.

57. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Lubaki NM, Ilinykh P, Pietzsch C, Tigabu B, Freiberg AN, Koup RA, Bukreyev A.

J Virol. 2013 Jul; (13):7471-85.

58. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs.

Qiu X, Wong G, Fernando L, Ennis J, Turner JD, Alimonti JB, Yao X, Kobinger GP.

J Virol. 2013 Jul; (13):7754-7.

59. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).

Sobarzo A, Groseth A, Dolnik O, Becker S, Lutwama JJ, Perelman E, Yavelsky V, Muhammad M, Kuehne AI, Marks RS, Dye JM, Lobel L.

J Infect Dis. 2013 Jul 15; (2):299-309.

60. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, Mühlberger E.

Virology. 2013 Jul 5; (2):135-45.

61. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses.

Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, Comunale MA, Du Y, Alonzi DS, Yu W, Ye H, Liu F, Guo JT, Mehta A, Cuconati A, Butters TD, Bavari S, Xu X, Block TM.

Antiviral Res. 2013 Jun; 98(3):432-40.

62. Ebolavirus nucleoprotein C-termini potently attract single domain antibodies enabling monoclonal affinity reagent sandwich assay (MARSA) formulation.

Sherwood LJ, Hayhurst A.

PLoS One. 2013; 8(4):e61232.

63. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ.

PLoS One. 2013; 8(4):e60579.

64. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.

Brudner M, Karpel M, Lear C, Chen L, Yantosca LM, Scully C, Sarraju A, Sokolovska A, Zariffard MR, Eisen DP, Mungall BA, Kotton DN, Omari A, Huang IC, Farzan M, Takahashi K, Stuart L, Stahl GL, Ezekowitz AB, Spear GT, Olinger GG, Schmidt EV, Michelow IC.

PLoS One. 2013; (4):e60838.

65. High-throughput virtual screening and docking studies of matrix protein vp40 of ebola virus.

Tamilvanan T, Hopper W.

Bioinformation. 2013; (6):286-92.

66. Ebola virus VP35 induces high-level production of recombinant TPL-2-ABIN-2-NF-κB1 p105 complex in co-transfected HEK-293 cells.

Gantke T, Boussouf S, Janzen J, Morrice NA, Howell S, Mühlberger E, Ley SC.

Biochem J. 2013 Jun 1; 452(2):359-65.

67. TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine.

Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S, Bu X, Farzan M, Freeman GJ, Umetsu DT, Dekruyff RH, Choe H.

PLoS Pathog. 2013 Mar; 9(3):e1003232.

68. Expression of concern: Serological evidence of Ebola virus infection in Indonesian orangutans.

PLOS ONE Editors.

PLoS One. 2013; 8(3):e60289.

69. Inhibition of Ebola Virus Infection: Identification of Niemann-Pick C1 as the Target by Optimization of a Chemical Probe.

Lee K, Ren T, Côté M, Gholamreza B, Misasi J, Bruchez A, Cunningham J.

ACS Med Chem Lett. 2013 Feb 14;4(2):239-243

70. Identification of a broad-spectrum inhibitor of viral RNA synthesis: validation of a prototype virus-based approach.

Filone CM, Hodges EN, Honeyman B, Bushkin GG, Boyd K, Platt A, Ni F, Strom K, Hensley L, Snyder JK, Connor JH.

Chem Biol. 2013 Mar 21; 20(3):424-33.

71. Phosphorylation of Ebola virus VP30 influences the composition of the viral nucleocapsid complex: impact on viral transcription and replication.

Biedenkopf N, Hartlieb B, Hoenen T, Becker S.

J Biol Chem. 2013 Apr 19; 288(16):11165-74.

72. Ebola virus does not block apoptotic signaling pathways.

Olejnik J, Alonso J, Schmidt KM, Yan Z, Wang W, Marzi A, Ebihara H, Yang J, Patterson JL, Ryabchikova E, Mühlberger E.

J Virol. 2013 May; 87(10):5384-96.

73. The context of gene expression defines the immunodominance hierarchy of cytomegalovirus antigens.

Dekhtiarenko I, Jarvis MA, Ruzsics Z, Čičin-Šain L.

J Immunol. 2013 Apr 1; 190(7):3399-409.

74. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection.

Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM.

PLoS One. 2013; 8(2):e56265.

75. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May; 87(9):4952-64.

76. The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells.

Nanbo A, Watanabe S, Halfmann P, Kawaoka Y.

Sci Rep. 2013; 3:1206.

77. An upstream open reading frame modulates ebola virus polymerase translation and virus replication.

Shabman RS, Hoenen T, Groseth A, Jabado O, Binning JM, Amarasinghe GK, Feldmann H, Basler CF.

PLoS Pathog. 2013 Jan; 9(1):e1003147.

78. Ebola virus exploits a monocyte differentiation program to promote its entry.

Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF.

J Virol. 2013 Apr; 87(7):3801-14.

79. Development of a panel of recombinase polymerase amplification assays for detection of biothreat agents.

Euler M, Wang Y, Heidenreich D, Patel P, Strohmeier O, Hakenberg S, Niedrig M, Hufert FT, Weidmann M.

J Clin Microbiol. 2013 Apr; 51(4):1110-7.

80. Ebola virus antibodies in fruit bats, bangladesh.

Olival KJ, Islam A, Yu M, Anthony SJ, Epstein JH, Khan SA, Khan SU, Crameri G, Wang LF, Lipkin WI, Luby SP, Daszak P.

Emerg Infect Dis. 2013 Feb; 19(2):270-3.

81. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I.

Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1893-8.

82. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.

Richardson JS, Pillet S, Bello AJ, Kobinger GP.

J Virol. 2013 Apr; 87(7):3668-77.

83. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner.

Martinez O, Ndungo E, Tantral L, Miller EH, Leung LW, Chandran K, Basler CF.

J Virol. 2013 Mar; 87(6):3324-34.

84. The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress.

Adu-Gyamfi E, Soni SP, Xue Y, Digman MA, Gratton E, Stahelin RV.

J Biol Chem. 2013 Feb 22; 288(8):5779-89.

85. Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.

Kajihara M, Nakayama E, Marzi A, Igarashi M, Feldmann H, Takada A.

J Gen Virol. 2013 Apr; 94(Pt 4):876-83.

86. Ethical dilemmas in protecting individual rights versus public protection in the case of infectious diseases.

Phua KL.

Infect Dis (Auckl). 2013 Feb 28; 6:1-5.

87. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques.

Twenhafel NA, Mattix ME, Johnson JC, Robinson CG, Pratt WD, Cashman KA, Wahl-Jensen V, Terry C, Olinger GG, Hensley LE, Honko AN.

Vet Pathol. 2013 May; 50(3):514-29.

88. ZAP inhibits murine gammaherpesvirus 68 ORF64 expression and is antagonized by RTA.

Xuan Y, Gong D, Qi J, Han C, Deng H, Gao G.

J Virol. 2013 Mar; 87(5):2735-43.

89. Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences.

Carroll SA, Towner JS, Sealy TK, McMullan LK, Khristova ML, Burt FJ, Swanepoel R, Rollin PE, Nichol ST.

J Virol. 2013 Mar; 87(5):2608-16.

90. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL.

J Infect Dis. 2013 Jul 15; 208(2):310-8.

91. Bayesian selection of nucleotide substitution models and their site assignments.

Wu CH, Suchard MA, Drummond AJ.

Mol Biol Evol. 2013 Mar; 30(3):669-88.

92. AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus.

Kondratowicz AS, Hunt CL, Davey RA, Cherry S, Maury WJ.

J Virol. 2013 Jan; 87(2):746-55.

93. A Syrian golden hamster model recapitulating ebola hemorrhagic fever.

Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, Rosenke R, Long D, Haddock E, Fischer E, Kawaoka Y, Feldmann H.

J Infect Dis. 2013 Jan 15;207(2):306-18.